Clinical trials: Psilocybin
Healthy Volunteers
Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers
The goal of this open-label, dose-escalation, prospective study is to evaluate the safety and psychological effects of a Psilocybin and D-Serine formulation in healthy volunteers. The main objectives are: 1.
- Trial name
- NCT07079930
- Testing
- Psilocybin and D-Serine, Physical Examination, Vital signs
- Where
- Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Disorders of Consciousness, Psychedelic Experiences
The Effects of Psilocybin on Shared Experience in Film Processing
The goal of this clinical trial is to learn whether certain methods of detecting awareness in vegetative or minimally conscious patients (using neuroimaging) are sensitive to the effects of psilocybin (a psychedelic drug).
- Trial name
- NCT06529939
- Testing
- Psilocybin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
Nicotine Dependence
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
One of the most promising lines of investigation for the therapeutic use of hallucinogens in the 1960s and 1970s was in the treatment of drug dependence.
- Trial name
- NCT01943994
- Testing
- Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic…
- Trial name
- 2C-B (NCT05523401)
- Testing
- 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psychedelic Experiences
Safety for Home Administration of Microdose Psilocybin Use
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants.
- Trial name
- NCT06450210
- Testing
- psilocybin trihydrate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Mental Health
Mindfulness-Assisted Psychedelic Therapy
The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is "Does mindfulness training enhance the effects of psychedelic therapy…
- Trial name
- MAPT (NCT06233344)
- Testing
- Psilocybin plus mindfulness training, Psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Meditation, Microdosing
Optimizing Microdosing and Meditation
The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2.
- Trial name
- OMM (NCT06560658)
- Testing
- Psilocybin, Meditation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National University of Natural Medicine
Prolonged Grief Disorder
Psilocybin for Prolonged Grief Disorder
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
- Trial name
- NCT06724289
- Testing
- Psilocybin 25 mg, Functional Magnetic Resonance Imaging (fMRI)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Depression - Major Depressive Disorder, Anhedonia
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1.
- Trial name
- NCT07490353
- Testing
- Psilocybin (Usona Institute), Risperidone 1 MG, MRI
- Where
- Austria
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy
Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs
This randomised controlled feasibility trial evaluates the Digital Intervention for Psychedelic Preparation (DIPP), a novel 21-day self-guided program designed to prepare individuals for psychedelic experiences.
- Trial name
- (DIPP-RCFT) (NCT06815653)
- Testing
- Psilocybin 25mg
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University College, London
Healthy
The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function
This study will test the effects of psilocybin on memory and cognition in healthy participants using computerized tasks and magnetic resonance imaging (MRI).
- Trial name
- NCT07079852
- Testing
- Psilocybin 15mg
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Manoj Doss
Healthy, Psychedelic Experiences
The ENHANCE Study: taVNS and Psilocybin
This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance…
- Conditions
- Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
- Trial name
- ENHANCE (NCT05866471)
- Testing
- Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research.
- Trial name
- NCT03912974
- Testing
- Escitalopram
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of…
- Trial name
- NCT05301608
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Autism Spectrum Disorder
Psilocybin in Adults With and Without Autism Spectrum Disorder
This study will test the hypothesis that brain systems are differentially regulated by serotonin in individuals with and without Autism Spectrum Disorder.
- Trial name
- PSILAUT (NCT05651126)
- Testing
- Psilocybin 5 mg, Psilocybin 2 mg
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- King's College London
Chronic Low Back Pain (CLBP), Physical Therapy
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical…
- Conditions
- Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
- Trial name
- NCT07306364
- Testing
- Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yale University
Mood (Psychological Function), Well Being
Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo.
- Conditions
- Mood (Psychological Function), Well Being, Mood, Healthy
- Trial name
- PRISMatic (NCT07610135)
- Testing
- Psilocybin, Pimavanserin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy Adults
Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.
Self-awareness, the capacity of becoming the object of one's own awareness, is a frontier of scientific knowledge. Over centuries, distinct philosophical and religious traditions have grappled with the subject, but only recently…
- Trial name
- NCT07732166
- Testing
- Psilocybin (Usona Institute), Niacin 100 mg
- Where
- Brazil
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pontifícia Universidade Católica do Rio de Janeiro